PLUS THERAPEUTICS, Inc
Cerenome, Inc. is a U.S.-based CNS oncology company developing precision diagnostics and targeted radiotherapeutics for central nervous system cancers. Its platform combines the CNSide laboratory-developed diagnostic, rhenium (186Re) obisbemeda, 188RNL-BAM, proprietary data, and related manufacturing capabilities through subsidiaries and external partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueRadiopharmaceutical candidates designed for localized treatment of CNS cancers.
CNSide® tests intended to identify tumor cells in cerebrospinal fluid.
188RNL-BAM is being developed for liver and other solid-organ cancers.
Proprietary production workflows, microfluidic chips, reagents, and analytical capabilities support development programs.
Customers
Cerenome’s commercial and development customers include hospitals, cancer centers, neuro-oncology practices, clinical laboratories, and research institutions that may use CNSide or participate in clinical programs. Future radiotherapeutic customers are expected to include healthcare providers and treatment centers seeking localized options for glioblastoma, leptomeningeal metastases, pediatric brain cancers, and other solid tumors. Payers and distribution or manufacturing partners also influence adoption through reimbursement, supply, and commercialization requirements.
Potential users of CNSide and localized radiotherapeutic procedures for complex CNS cancers.
Use diagnostic information and targeted treatment options in CNS cancer management.
Perform or support CNSide testing and related sample-processing workflows.
Participate in trials and generate clinical evidence for product candidates.
Provide development, manufacturing, supply, or commercialization capabilities.
Strategy
Cerenome is building an integrated CNS oncology model that links precision diagnostics, targeted radiotherapeutics, and proprietary clinical data. Near-term priorities include commercializing CNSide, advancing rhenium (186Re) obisbemeda and 188RNL-BAM through clinical development, and expanding standardized production capacity. The company also uses contract research and manufacturing partners to extend capabilities while building internal analytical, ERP, and operational infrastructure.
Diagnostic revenue can establish a commercial entry point before therapeutic approvals.
Clinical validation and regulatory progress are required to convert candidates into products.
Standardized manufacturing and planning support higher clinical and commercial volumes.
Combining diagnostics and therapeutics may improve disease characterization and treatment positioning.
Geography
Cerenome is headquartered and principally operates in the United States, with operations and facility expansion centered in Houston, Texas. Its clinical, regulatory, manufacturing, and commercial activities are U.S.-focused in the available reports, while future product candidates may require approvals and commercialization capabilities in additional jurisdictions. No country-level revenue percentages are disclosed in the provided excerpts.
Risks
Cerenome remains dependent on successful clinical development, regulatory approval, reimbursement, and commercialization of investigational products. Its development model also relies heavily on CROs, hospitals, clinical investigators, and CMOs, creating execution, supply, quality, and data-integrity exposure. Continuing losses and operating cash use increase financing and going-concern risk while competition may reduce future market access or pricing.
- Clinical development failureImpact: CriticalLikelihood: High
Negative efficacy, safety, or manufacturing data could end programs before approval.
Exposure: Rhenium (186Re) obisbemeda and 188RNL-BAM
- Regulatory approval failureImpact: CriticalLikelihood: High
Radiopharmaceuticals and diagnostics face extensive, costly, and unpredictable requirements.
Exposure: FDA and other health authorities
- Financing and going-concern riskImpact: CriticalLikelihood: High
Operating cash use and continuing losses may require additional capital before products generate material revenue.
Exposure: Corporate liquidity and development funding
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
CMO capacity, compliance, quality, or supply interruptions could delay trials or launch.
Exposure - Third-party clinical executionImpact: HighLikelihood: Medium
CRO, hospital, or investigator failures could delay trials or compromise data integrity.
Exposure: Clinical trial operations
- Reimbursement and market adoptionImpact: HighLikelihood: Medium
Inadequate coverage, pricing, or treatment convenience could restrict demand.
Exposure: Future CNSide and radiotherapeutic commercialization
- Competitive displacementImpact: HighLikelihood: Medium
Other biotechnology, pharmaceutical, device, and diagnostic companies may deliver safer or more effective alternatives.
Exposure: CNS oncology and laboratory diagnostics
Accounting
Judgemental itemsCommercial CNSide billing requires revenue to be recognized as testing obligations are fulfilled.
Impact: Timing and classification of emerging diagnostic revenue
Estimates related to grants and awards affect recognized assets, liabilities, and expenses.
Impact: Potential changes to operating results and balance-sheet values
Impairment judgments can materially change asset carrying values and reported losses.
Impact: Non-cash impairment expense
Equity awards require valuation assumptions and increase reported operating expense.
Impact: Expense recognition and dilution analysis
Warrant valuation depends on market and other assumptions and may change between periods.
Impact: Non-cash gains or losses and liability balances
Continuing losses and operating cash use require evaluation of funding and liability settlement assumptions.
Impact: Financial statement disclosure and investor risk assessment
Similar listed companies
Publicly listed companies with a comparable business focus.
CNS Pharmaceuticals, Inc.
CNSP · Pharmaceutical Preparations
Perspective Therapeutics, Inc.
CATX · Pharmaceutical Preparations
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026